Cardiovascular Systems Inc(NASDAQ:CSII) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $48.46M. Analysts estimated a revenue of $46.01M. Earnings per share were $-0.15. Analysts had estimated an EPS of $-0.20.
Cardiovascular Systems Inc (CSII) made into the market gainers list on Fridays trading session with the shares advancing 0.55% or 0.12 points. Due to strong positive momentum, the stock ended at $21.86, which is also near the day’s high of $22.18. The stock began the session at $21.78 and the volume stood at 2,41,363 shares. The 52-week high of the shares is $24.9 and the 52 week low is $7.5. The company has a current market capitalization of $714 M and it has 3,26,73,703 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Leslie Trigg (director) sold 3,500 shares at $33.86 per share price.Also, On Feb 25, 2016, Capital Management Llc Camber (10% owner) purchased 250,000 shares at $7.55 per share price.On Jan 25, 2016, Scott R. Ward (CEO) purchased 2,700 shares at $9.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Cardiovascular Systems Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee. Its products include Stealth 360 degree Peripheral Orbital Atherectomy System (OAS); the Diamondback 360 Peripheral OAS (Diamondback 360 Peripheral) and Diamondback 360 Peripheral Diamondback 360 60cm Peripheral OAS and Diamondback 360 4 French 1.25 Peripheral (collectively called as peripheral arterial disease systems (PAD systems)). Its coronary product the Diamondback 360 Coronary OAS (CAD System) is a catheter-based platform designed to facilitate stent delivery in patients with coronary arterial disease (CAD). The CAD System design is customized for the coronary application.